Skip to main content

Empaveli Prices, Coupons and Patient Assistance Programs

Empaveli (pegcetacoplan) is a member of the selective immunosuppressants drug class and is commonly used for Paroxysmal Nocturnal Hemoglobinuria.

The cost for Empaveli subcutaneous solution (1080 mg/20 mL) is around $4,953 for a supply of 20 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.

Empaveli is available as a brand name drug only, a generic version is not yet available. View generic Empaveli availability for more details.

Empaveli prices

Subcutaneous Solution

Quantity Per unit Price
20 milliliters $247.65 $4,953.04

Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.

Empaveli Coupons, Copay Cards and Rebates

Empaveli offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.

Drugs.com Printable Discount Card

The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.

Print Free Discount Card

Note: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.

Empaveli Apellis Co-Pay Program

Eligible commercially insured patients may receive financial assistance to help cover co-pay and co-insurance costs; for additional information contact the program 866-692-7527.

Applies to:
Empaveli
Number of uses:
Per prescription until program expires

Form more information phone: 866-692-7527 or Visit website

Empaveli Apellis Bridge Program

Eligible commercially insured patients may receive a temporary supply of medication if experiencing a delay or change in insurance; for additional information contact the program 866-692-7527.

Applies to:
Empaveli
Number of uses:
Temporary Assistance

Form more information phone: 866-692-7527 or Visit website

Empaveli Trial Offer

Eligible insured patients may receive 8 weeks of medication at no cost; for additional information contact the program 866-692-7527.

Applies to:
Empaveli
Number of uses:
One-time offer

Form more information phone: 866-692-7527 or Visit website

Patient Assistance & Copay Programs for Empaveli

Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.

Provider: Patient Access Network Foundation (PAN)

Eligibility requirements:
  1. *See Additional Information section below
  2. Between 400-500% of FPL
  3. FDA Approved Diagnosis - See Program Website for Details
  4. Must reside and receive treatment in US
  5. *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
Applicable drugs:
  • Empaveli (pegcetacoplan) Injection; Subcutaneous

More information please phone: 866-316-7263 Visit Website

Provider: ApellisAssist: Empaveli

Eligibility requirements:
  1. Determined case by case
  2. Based on FPL
  3. FDA-approved diagnosis
  4. Must be residing in the US or US territory
  5. Prescribing Physician, Healthcare Facilities, Pharmacies and Patients must enroll into the Risk Evaluation and Mitigation Strategy (REMS) Program prior to initiating the patient on treatment with (Empaveli). Co-payment assistance, patient support, and patient assistance programs are available for eligible patients. This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details. Please visit www.empaveli.com or call (866) 692-7527 for more information.
Applicable drugs:
  • Empaveli (pegcetacoplan) Injection; Subcutaneous

More information please phone: 866-692-7527 Visit Website

Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.